P2Y12

Source: Wikipedia, the free encyclopedia.
This article is about the receptor. For the class of medications, see Adenosine diphosphate receptor inhibitor.
P2RY12
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl

ENSG00000169313

ENSMUSG00000036353

UniProt

Q9H244

Q9CPV9

RefSeq (mRNA)

NM_176876
NM_022788

NM_027571
NM_001357007
NM_001357008
NM_001357010

RefSeq (protein)

NP_073625
NP_795345

NP_081847
NP_001343936
NP_001343937
NP_001343939

Location (UCSC)Chr 3: 151.34 – 151.38 MbChr 3: 59.12 – 59.17 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

P2Y12 is a

platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene.[8]

In the field of

purinergic signaling, the P2Y12 protein on the periphery is found mainly but not exclusively on the surface of blood platelets, and is an important regulator in blood clotting.[9] In the central nervous system, this receptor has been found expressed exclusively on microglia, where it is necessary for physiological and pathological microglial actions, such as monitoring neuronal functions and microglial neuroprotection.[10]

P2Y12 antagonists

The drugs

antiplatelet agents.[5]

For acute coronary syndrome

The combination of a P2Y12 inhibitor and aspirin, called dual antiplatelet treatment, remains the first-line treatment for acute coronary syndrome. A 2019 randomized trial suggested that prasugrel is superior to ticagrelor.[11]

Antiplatelet treatment of STEMI

In patients undergoing primary percutaneous coronary intervention (PCI) for an ST-segment elevation myocardial infarction (STEMI), US,[12] European,[13] and Canadian[14] guidelines recommend that a P2Y12 inhibitor should be administered as soon as possible, although it is unclear whether administration of these medications before the patient arrives at the hospital confers additional benefits compared with in-hospital administration.[14]

On the other hand, P2Y12 inhibitors do not change the risk of death when given as a pretreatment prior to routine PCI in people who have had a non-ST-elevation myocardial infarction (

NSTEMI). Though, a P2Y12 inhibitor in addition to aspirin should be administered for up to 12 months to most patients with non-ST-elevation acute coronary syndrome. They do however increase the risk of bleeding and decrease the risk of further cardiovascular problems. Thus their routine use in this context is of questionable value.[15]

A

major adverse cardiac events (MACE) patients found that use of prasugrel was associated with lower mortality and MACE than other drugs in this class (clopidogrel and ticagrelor).[16]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000169313 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000036353 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^
    S2CID 4423579
    .
  6. PMID 11502870
    .
  7. PMID 16368572
    .
  8. ^ "Entrez Gene: P2RY12 purinergic receptor P2Y, G-protein coupled, 12".
  9. PMID 14755328
    .
  10. S2CID 209343260
    .
  11. PMID 31475799
    .
  12. PMID 23247304
    .
  13. PMID 28886621
    .
  14. ^
    PMID 30760415
    .
  15. PMID 25954988
    .
  16. PMID 27198684
    .

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=P2Y12&oldid=1189253117"
This page is based on the copyrighted Wikipedia article: P2Y12. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy